This file photo provided by Samsung Biologics shows its No. 4 plant in Songdo, just west of Seoul. (Image courtesy of Yonhap)
SEOUL, Dec. 22 (Korea Bizwire) — Samsung Biologics Co., the contract drug manufacturing arm of South Korea’s Samsung Group, said Monday that its U.S. subsidiary will acquire a biopharmaceutical manufacturing facility from GSK for 413.6 billion won ($280 million), marking its first manufacturing footprint in the United States.
Samsung Biologics America has agreed to purchase a 100% stake in Human Genome Sciences, with the transaction expected to close in the first quarter of 2026, the company said.
The acquisition gives Samsung Biologics a U.S.-based production site as it seeks to expand its global supply network and respond to rising demand for biologic drugs, amid growing emphasis by pharmaceutical companies on geographically diversified manufacturing.
The facility, located in Rockville, includes two manufacturing plants with a combined drug substance capacity of 60,000 liters and supports both clinical- and commercial-scale production. The site sits within one of the largest biopharmaceutical clusters in the U.S., providing access to skilled labor and established industry infrastructure.
Samsung Biologics said it plans further investments to expand the facility’s production capacity and technical capabilities. By integrating the site into its existing network, the company aims to offer clients flexible, multi-site manufacturing options across the U.S. and South Korea, reducing supply-chain risk for critical biologic medicines.
“This acquisition strengthens our ability to provide a stable and reliable supply of biologics to global customers,” said John Rim, chief executive of Samsung Biologics.
Samsung Biologics currently operates five manufacturing plants in Songdo, west of Seoul, with a total production capacity of 785,000 liters, making it one of the world’s largest contract development and manufacturing organizations for biologics.
Ashley Song (ashley@koreabizwire.com)
